| | |
| Clinical data | |
|---|---|
| Other names | YK11; (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester |
| Drug class | Selective androgen receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C25H34O6 |
| Molar mass | 430.541 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
YK-11 is a synthetic steroidal selective androgen receptor modulator (SARM). [1] [2] It is a gene-selective partial agonist of the androgen receptor (AR) and does not induce the physical interaction between the NTD/AF1 and LBD/AF2 (known as the N/C interaction), which is required for full transactivation of the AR. [1] [2] The drug has anabolic activity in vitro in C2C12 myoblasts and shows greater potency than dihydrotestosterone (DHT) in this regard. [2] It has been investigated as a potential treatment for sepsis-induced muscle wasting in animal studies. [3] YK-11 has been encountered as a novel designer drug. [4]